Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Larry Liebman who wrote (3685)	1/27/1998 8:57:00 AM
From: David S.	Read Replies (1) \| Respond to of 6136

Currently, for longs, I am looking in other sectors. It's kind of funny, in that when I pointed out that other well financed companies were also involved in biotechish attempts at putting Kleenex out of business, people make the wrong assumptions about that. For example, if Bayer's cold drug fails, that Bayer will fail as company - Sometimes people don't know when I'm just kidding a little. I think John does illustrate a good point re: biotech though, he states that AGPH has the cure for the common cold. Well, I went to a Rexall pharmacy in my neighborhood yesterday, asked the pharmacist about it, and the woman thought I was nuts. (she could be right, but for a different reason=joke) to say that any biotech company has a,b, or c cure or treatment when a drug or even drug CANDIDATE is in early clinicals or preclinical development is an error. I'd also say to be careful of investing in even areas where the market may be huge, but where 50 zillion other drug companies are investing, which happens to mean cancer. It also includes AIDS, but in general, I think the investing public, is a bit more sophisticated than people who do biotech investing in companies that have a major cancer push. That's all - best of luck.